サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1770156

双極性障害治療薬の世界市場

Bipolar Disorder Therapeutics

出版日
ページ情報
英文 380 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.47円
双極性障害治療薬の世界市場
出版日: 2025年07月14日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 380 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

双極性障害治療薬の世界市場は2030年までに78億米ドルに到達

2024年に63億米ドルと推定される双極性障害治療薬の世界市場は、分析期間2024-2030年にCAGR 3.4%で成長し、2030年には78億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗精神病薬は、CAGR 3.3%を記録し、分析期間終了時には35億米ドルに達すると予測されます。抗けいれん薬セグメントの成長率は、分析期間中CAGR 4.3％と推定されます。

米国市場は28億米ドルと推定、中国はCAGR 5.5％で成長予測

米国の双極性障害治療薬市場は、2024年に28億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに6億3,700万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは5.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.2%と3.3%と予測されています。欧州では、ドイツがCAGR 2.9%で成長すると予測されています。

世界の双極性障害治療薬市場- 主要動向と促進要因まとめ

双極性障害は、躁状態の高揚と抑うつ状態の下降を含む極端な気分変動を特徴とする慢性的な精神疾患であり、症状を管理し生活の質を改善するための包括的な治療戦略が必要です。双極性障害の主な治療アプローチには、薬物治療、心理療法、生活習慣の改善が含まれます。薬物療法は双極性障害管理の要であり、リチウムなどの気分安定薬、バルプロ酸塩やラモトリギンなどの抗けいれん薬、クエチアピンやアリピプラゾールなどの非定型抗精神病薬がよく処方されます。これらの薬物は気分を安定させ、再発を予防し、躁病エピソードやうつ病エピソードの重症度を軽減するのに役立ちます。薬物療法に加えて、認知行動療法（CBT）、心理教育、家族療法などの心理療法的介入は、患者が自分の状態を理解し、対処戦略を立て、治療アドヒアランスを維持するために不可欠です。

双極性障害治療薬の開発と最適化は、現在進行中の研究と臨床試験から大きな影響を受けています。神経科学の開発と双極性障害の病態生理の理解が進んだことで、より的を絞った治療法が開発されるようになりました。例えば、双極性障害における神経伝達物質と神経可塑性の役割に関する調査により、特定の神経経路を標的とした新しい薬理学的薬剤への道が開かれました。さらに、モバイルアプリや遠隔精神医療などのデジタルヘルス技術の統合により、精神療法の提供や治療アドヒアランスのモニタリングが強化されています。これらの技術は、患者によりアクセスしやすく柔軟な治療選択肢を提供し、継続的なケアと症状のリアルタイムモニタリングを容易にします。

双極性障害治療薬市場の成長は、精神疾患の有病率の上昇、精神疾患に対する認識と診断の高まりなど、いくつかの要因によってもたらされます。メンタルヘルスに対する偏見が減少し、治療を求める人が増えるにつれて、双極性障害の効果的な治療法に対する需要が急増しています。ドラッグデリバリーシステムの技術的進歩と長時間作用型注射薬の開発により、患者のコンプライアンスと治療成績が向上しています。さらに、製薬企業による研究開発への多額の投資は、より優れた有効性と安全性プロファイルを提供する革新的な治療法の導入につながっています。遠隔医療サービスの拡大も、特にCOVID-19パンデミックの状況において、精神医療への遠隔アクセスを提供することで重要な役割を果たしています。さらに、メンタルヘルス・インフラと資金調達の改善を目的とした政府の取り組みや政策が市場の成長を支えています。個人の遺伝子やバイオマーカーのプロファイルに合わせて治療を行う個別化医療が重視されるようになり、双極性障害治療薬の進歩がさらに促進されると予想されます。

セグメント

薬剤クラス別（抗精神病薬、抗けいれん薬、気分安定薬、抗うつ薬、抗不安薬）

調査対象企業の例

  • Astellas Pharma, Inc.
  • Aurobindo Pharma Ltd.
  • Aphios Corporation
  • Bionomics Ltd.
  • AbbVie, Inc.
  • Amneal Pharmaceuticals, Inc.
  • Alexza Pharmaceuticals
  • Alkermes PLC
  • Avineuro Pharmaceuticals, Inc.
  • Azevan Pharmaceuticals, Inc.
  • Alembic Pharmaceuticals Limited
  • Alfresa Pharma Corporation
  • Bentley & Remington（P）Ltd.
  • Actiza Pharmaceutical Pvt., Ltd.
  • Acadia Pharmaceuticals, Inc.

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-6202

Global Bipolar Disorder Therapeutics Market to Reach US$7.8 Billion by 2030

The global market for Bipolar Disorder Therapeutics estimated at US$6.3 Billion in the year 2024, is expected to reach US$7.8 Billion by 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. Antipsychotic Drugs, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$3.5 Billion by the end of the analysis period. Growth in the Anticonvulsants segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.8 Billion While China is Forecast to Grow at 5.5% CAGR

The Bipolar Disorder Therapeutics market in the U.S. is estimated at US$2.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$637.0 Million by the year 2030 trailing a CAGR of 5.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.2% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Bipolar Disorder Therapeutics Market - Key Trends & Drivers Summarized

Bipolar disorder, a chronic mental health condition characterized by extreme mood swings including manic highs and depressive lows, requires comprehensive therapeutic strategies to manage symptoms and improve quality of life. The primary therapeutic approaches for bipolar disorder involve pharmacological treatments, psychotherapy, and lifestyle modifications. Medications are the cornerstone of bipolar disorder management, with mood stabilizers such as lithium, anticonvulsants like valproate and lamotrigine, and atypical antipsychotics like quetiapine and aripiprazole being commonly prescribed. These medications help to stabilize mood, prevent relapse, and reduce the severity of manic and depressive episodes. In addition to pharmacotherapy, psychotherapeutic interventions such as cognitive-behavioral therapy (CBT), psychoeducation, and family therapy are essential in helping patients understand their condition, develop coping strategies, and maintain treatment adherence.

The development and optimization of bipolar disorder therapeutics have been significantly influenced by ongoing research and clinical trials. Advances in neuroscience and a better understanding of the pathophysiology of bipolar disorder have led to the development of more targeted treatments. For instance, research into the role of neurotransmitters and neuroplasticity in bipolar disorder has paved the way for novel pharmacological agents aimed at specific neural pathways. Additionally, the integration of digital health technologies, such as mobile apps and telepsychiatry, has enhanced the delivery of psychotherapy and monitoring of treatment adherence. These technologies provide patients with more accessible and flexible therapeutic options, facilitating continuous care and real-time monitoring of symptoms, which are crucial for managing a condition characterized by episodic fluctuations.

The growth in the bipolar disorder therapeutics market is driven by several factors, including the rising prevalence of the disorder and the increasing awareness and diagnosis of mental health conditions. As mental health stigma decreases and more people seek treatment, the demand for effective bipolar disorder therapies has surged. Technological advancements in drug delivery systems and the development of long-acting injectable medications have improved patient compliance and outcomes. Furthermore, significant investment in research and development by pharmaceutical companies is leading to the introduction of innovative therapies that offer better efficacy and safety profiles. The expansion of telehealth services has also played a critical role, especially in the context of the COVID-19 pandemic, by providing remote access to mental health care. Additionally, government initiatives and policies aimed at improving mental health infrastructure and funding are supporting market growth. The growing emphasis on personalized medicine, where treatments are tailored to the individual's genetic and biomarker profiles, is expected to further drive advancements in bipolar disorder therapeutics.

SCOPE OF STUDY:

The report analyzes the Bipolar Disorder Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs, Anti-Anxiety Drugs)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 102 Featured) -

  • Astellas Pharma, Inc.
  • Aurobindo Pharma Ltd.
  • Aphios Corporation
  • Bionomics Ltd.
  • AbbVie, Inc.
  • Amneal Pharmaceuticals, Inc.
  • Alexza Pharmaceuticals
  • Alkermes PLC
  • Avineuro Pharmaceuticals, Inc.
  • Azevan Pharmaceuticals, Inc.
  • Alembic Pharmaceuticals Limited
  • Alfresa Pharma Corporation
  • Bentley & Remington (P) Ltd.
  • Actiza Pharmaceutical Pvt., Ltd.
  • Acadia Pharmaceuticals, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Tariff Impact on Global Supply Chain Patterns
    • Bipolar Disorder Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • Bipolar Disorder Therapeutics - A Prelude
    • Symptoms of Bipolar Disorder
    • Mood Episode - A Major Symptom
    • Manic Episode Vs Depressive Episode
    • Causes of Bipolar Disorder
    • Types of Bipolar Disorder
    • Co-morbidities of Bipolar Disorder
    • Segments
    • Antipsychotic Drugs
    • Antidepressant Drugs
    • Anticonvulsants
    • Mood Stabilizers
    • Anti-Anxiety Drugs
    • Select Drugs for Bipolar Disorder Treatment by Drug Class
    • Global Economic Update
    • Global Market Analysis and Prospects
    • Bipolar Disorder Therapeutics Market Set to Witness Rapid Growth
    • Regional Market Analysis
    • Treatment Analysis
    • Anti-Psychotics
    • Pipeline Drugs in Phase III for Bipolar Disorder
    • Select Anti-Psychotic Drugs
    • A Review of Anti-Psychotics
    • Indications of Antipsychotics
    • An Effective Adjunctive Therapy
    • Off-label Uses
    • Efficacy - Marred by Lack of Evidence Base
    • Types of Antipsychotics
    • Side Effects of Antipsychotics
    • Symptoms of Antipsychotics Withdrawal
    • Anti-Depressants
    • Market Overview
    • Anti-Depressant Market: Percentage Share Breakdown by Depressive Disorder Type
    • Anti-Depressant Treatment
    • Select Antidepressant Drugs
    • Recent Approvals of Anti-Depressants
    • Pipeline Drugs in Phase III for Depressive Disorder
    • A Review of Depression
    • Types of Depressive Disorders
    • Available Treatment
    • Working of Antidepressants
    • Ranking of Antidepressants in Terms of Efficacy
    • Types of Antidepressants
    • NMDA Receptor Antagonists
    • Acetylcholinesterase Inhibitors
    • Selective Serotonin Reuptake Inhibitors (SSRIs)
    • Serotonin-norepinephrine Reuptake Inhibitors (SNRI)
    • Tricyclic Antidepressants
    • Monoamine Oxidase Inhibitors (MOI)
    • Benzodiazepines
    • Beta Blockers
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Market Gains to Continue Amid Rising Prevalence of Bipolar Disorder
    • Awareness Programs Augment Prospects
    • Increasing R&D Activities Drive the Global Bipolar Disorder Therapeutics Market
    • Technology Advancements Widen Addressable Market
    • Social Inclusion of People with Mental Illnesses Augurs Well
    • Online Self-Management Tools Improve Treatment Outcomes
    • Increasing Product R&D, Approvals & Launches Support Market Expansion
    • Side Effects of Bipolar Disorder Drugs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Bipolar Disorder Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Bipolar Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Antipsychotic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Antipsychotic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Antipsychotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Anticonvulsants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Mood Stabilizers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Mood Stabilizers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Mood Stabilizers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Antidepressant Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Antidepressant Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Antidepressant Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Anti-anxiety Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Anti-anxiety Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Anti-anxiety Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 19: World Bipolar Disorder Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: Canada 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030
  • JAPAN
    • Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Japan Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: Japan 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030
  • CHINA
    • Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 29: China Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: China Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: China 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030
  • EUROPE
    • Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Bipolar Disorder Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Europe 15-Year Perspective for Bipolar Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Europe 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030
  • FRANCE
    • Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 38: France Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: France Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: France 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030
  • GERMANY
    • Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 41: Germany Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Germany Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Germany 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Italy Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Italy 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 47: UK Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: UK Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: UK 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 50: Spain Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Spain Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Spain 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 53: Russia Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Russia Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Russia 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Rest of Europe Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Rest of Europe 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Bipolar Disorder Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Asia-Pacific 15-Year Perspective for Bipolar Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Asia-Pacific 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 65: Australia Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Australia Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Australia 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030
  • INDIA
    • Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 68: India Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: India Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: India 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 71: South Korea Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: South Korea Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: South Korea 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Rest of Asia-Pacific Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Rest of Asia-Pacific 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Bipolar Disorder Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Latin America 15-Year Perspective for Bipolar Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Latin America 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 83: Argentina Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Argentina Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Argentina 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 86: Brazil Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Brazil Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Brazil 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 89: Mexico Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Mexico Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Mexico 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Latin America Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Latin America 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Bipolar Disorder Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Middle East 15-Year Perspective for Bipolar Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Middle East 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 101: Iran Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Iran Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Iran 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 104: Israel Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Israel Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Israel 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Saudi Arabia Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Saudi Arabia 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 110: UAE Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UAE Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: UAE 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Rest of Middle East Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Rest of Middle East 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030
  • AFRICA
    • Bipolar Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 116: Africa Recent Past, Current & Future Analysis for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Africa Historic Review for Bipolar Disorder Therapeutics by Drug Class - Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Africa 15-Year Perspective for Bipolar Disorder Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antipsychotic Drugs, Anticonvulsants, Mood Stabilizers, Antidepressant Drugs and Anti-anxiety Drugs for the Years 2015, 2025 & 2030

IV. COMPETITION